Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high229.00 11/05/17
52 week low1.95 21/11/17
52 week change -148.50 (-66.74%)
4 week volume661,998 30/03/18
price74.00
price date1524662790
close74.00

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Latest NewsMore

ReNeuron wins grant for retinal cell therapy development

ReNeuron, a developer of cell-based therapeutics, is the lead industry participant in a new 1.5 million grant award from th...

Wins grant for retinal cell therapy development

RNS Number: 3700L ReNeuron Group plc 19 April 2018 19 April 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Wins grant for retinal cell therapy development ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics , is pleased to announce that it is the lead industry participant in a new 1.5...

Appointment of US-based Chief Medical Officer

RNS Number: 4495K ReNeuron Group plc 10 April 2018 10 April 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Appointment of US-based Chief Medical Officer ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, i s pleased to announce that Dr Richard Beckman has joined the Comp...

Product Development Update

RNS Number: 8408I ReNeuron Group plc 26 March 2018 26 March 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Product Development Update ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, i s pleased to provide an update across its research and development programmes. Highl...

Block Listing Review and TVR

RNS Number: 3082G ReNeuron Group plc 01 March 2018 1 March 2018 AIM: RENE ReNeuron Group plc Block Listing Review and Total Voting Rights ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Co...

Block Listing Application

RNS Number: 0611F ReNeuron Group plc 16 February 2018 16 February 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Block Listing Application ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that an application has been made to the London Stock Exchange plc ...

Positive pre-clinical data in nerve injury

RNS Number: 7283E ReNeuron Group plc 13 February 2018 13 February 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Positive pre-clinical data in nerve injury Positive pre-clinical data published using ReNeuron's CTX cells in artificial nerve tissue generated as part of a grant-funded collaboration ReNeuron Group plc (AIM: RENE), a UK...

ReNeuron presents treatment trial results

ReNeuron Group said that positive long-term clinical trial data for a stroke disability treatment was accepted for a podium...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Latest discussion posts More

  • Re: Unbelievable

    I'm so peed off with the lack of management of this outfit. Micheal Hunt did an excellent job prior to that waste of space Olav H.....In my humble opinion, he needs sacking and ...
    19-Apr-2018
    fredd1eboy
  • Re: Unbelievable

    Except the board never buy shares, even at these levels, which is quite disheartening. I'm not sure how long some employees will hang around for, after a decade of poor pay and ...
    19-Apr-2018
    Prospero68
  • Re: Unbelievable

    To be fair, I wouldn't expect anybody to buy based on that news. Volumes aren't exactly high, drops are disproportionate. The board should take advantage of disproportionate ...
    19-Apr-2018
    grizzlyb

Users' HoldingsMore

Users who hold Reneuron Group also hold..

Codes & Symbols

ISINGB00BF5G6K95
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE